WeylChem to Produce Grignard Reagents on an Industrial Scale
News Sep 15, 2008
WeylChem has announced its intention to produce reagents on an industrial scale for major manufacturers of pharmaceuticals, agrochemicals and poly-functionalized products. A complete series of Grignard type reagents will be produced at the company’s Elgin, South Carolina facility.
The scale-up in Grignard reagent production is in response to an industry need for suppliers with the capability to deliver higher volumes than is currently available in the United States.
WeylChem offers the technical packages and production capacity to reliably supply manufacturers with starter reactions, like the Grignard reaction. Grignard chemistry is an important tool in the formation of carbon-carbon bonds and for the formation of carbon-phosphorus, carbon-tin, carbon-silicon, carbon-boron and other carbon-heteroatom bonds.
According to Alain Angelac, Sales and Marketing Project Manager, the move to supply the market with Grignards on an industrial scale is commensurate with changes taking place in the manufacturing programs of large multi-national manufacturers. “A number of our customers have asked us if we can supply them with Grignard reagents on a commercial scale as they reconfigure plants for new projects, or as they adopt chemistries and processes that make it uneconomical to produce the reagents in-house,” he said.
“Our customers know we have a long history of sound production and management practices – the kind needed to reliably deliver hazardous chemistry wherever it is needed, like Grignard reagents. And they know that we have the ability to make these reagents on a scale large enough to ensure reliable supplies in the long-term,” he said.
“With the start-up of commercial scale Grignard reagents production at Elgin, we have taken the first step in serving customers as both a supplier of custom synthesis and a producer of functional products,” he said.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE